UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer

Birtle, AJ; Newby, JC; Harland, SJ; (2004) Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. British Journal of Cancer , 91 (8) pp. 1472-1476.

Full text not available from this repository.

Abstract

The aim of this study was to examine the efficacy and toxicity of the epirubicin, carboplatin and 5-fluorouracil (ECarboF) regime in patients aged 70 or less with metastatic prostate cancer resistant to LHRH analogues. The majority of patients had previously received steroids as part of their systemic management and had progressive disease on steroids. In total, 80 patients were treated over a 6-year period, with objective response rates (PSA or radiological) of 45% and median time to relapse of 9.5 months. Median survival of the group was 9.2 months. In all, 32% of patients were alive at 12 months. Grade 3/4 neutropenia occurred in 34% of patients with an 8.7% rate of neutropenic sepsis. Grade 3/4 nonhaematological toxicity occurred in 28% of patients. For a substantial minority of patients with hormone refractory prostate cancer, combination chemotherapy can induce remission of significant duration. While similar responses have been documented for systemic cytotoxic-steroid combinations, the responses in this study are likely to reflect the activity of cytotoxic drugs alone

Type: Article
Title: Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
Additional information: WoS ID: 000224412500011 JournalEnglishArticle20NATURE PUBLISHING GROUPBERRY W, 2002, J UROLOGY, V168, P2439; BERRY W, 2001, SEMIN ONCOL S15, V28, P8; BONNEFOI H, 1996, BRIT J CANCER, V73, P391; BRAUSI M, 1995, EUR J CANCER, V31, P1622; BUBLEY GJ, 1999, J CLIN ONCOL, V17, P3461; CHAO D, 1997, EUR J CANCER, V33, P1230; DENIS LJ, 1993, UROLOGY, V42, P119; FIGG WD, 1996, CANCER INVEST, V14, P513; FOSSA SD, 1992, ANN ONCOL, V3, P361; FOSSA SD, 2001, J CLIN ONCOL, V19, P62; HORWITZ EM, 1998, INT J RADIAT ONCOL, V41, P267; KANTOFF PW, 2001, J CLIN ONCOL, V19, P3025; KELLY WK, 1993, J CLIN ONCOL, V11, P607; NEWBY JC, 1999, BCRM M; PETRYLAK DP, 2002, SEMIN UROL ONCOL, V20, P31; ROSS P, 2002, J CLIN ONCOL, V20, P1996; SMITH DC, 1998, J CLIN ONCOL, V16, P1835; TANNOCK IF, 1996, J CLIN ONCOL, V14, P1756; VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93; WEITZMAN AL, 2000, J UROLOGY, V163, P8340OCT 18861JJLONDONBirtle AJ Middlesex Hosp, Meyerstein Inst Oncol, Mortimer St, London W1N 8AA, EnglandBRIT J CANCERMACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Keywords: ANTIGEN, CANCER, CARBOPLATIN, CHEMOTHERAPY, CISPLATIN, COMBINATION, COMBINATION CHEMOTHERAPY, DISEASE, DOCETAXEL, ECarboF, EFFICACY, FLUTAMIDE, GENITOURINARY GROUP, guidelines, MANAGEMENT, PHASE-II, PREDNISONE, prostate cancer, PROSTATE-CANCER, RANDOMIZED TRIAL, response, SURVIVAL, THERAPY, TOXICITY
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/70206
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item